The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

Inclusion Criteria: * Has a diagnosis of hepatocellular carcinoma confirmed by histology or cytology； * Barcelona Clinic Liver Cancer (BCLC) Stage B or C； * Age ≥18 years or ≤75 years for both genders； * ECOG performance status: 0-1； * Child Pugh score≤7； * LVEF≥50% or above LLN of the research institution； * Enough organ function； * Has at least one measurable lesion based on RECIST 1.1； * Life expectancy ≥3 months； * Patients must be able to understand and willing to sign a written informed consent document； Exclusion Criteria: * Fibrous lamina hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma etc; * Tumor thrombus invasion at the main portal vein (Vp4), inferior vena cava or heart involvement; * Subjects who have previously received immune checkpoint inhibitors (such as anti-PD-1/L1, CTLA-4, etc.); * Subjects who have received liver local treatment (transcatheter chemoembolization, transcatheter embolization, hepatic artery perfusion, radiotherapy, radioembolization or ablation) within 4 weeks before administration; * Subjects who need corticosteroids or immunosuppressive agents for systemic therapy; * Any previous or current active autoimmune disease or history of autoimmune disease; * History of hepatic encephalopathy or liver transplantation; * History of interstitial lung disease or non-infectious pneumonia; * History of allergic reactions to related drugs; * Clinically obvious gastrointestinal abnormalities, which may affect the intake, transport or absorption of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or patients undergoing total gastrectomy; * With serious systemic diseases such as heart disease and cerebrovascular disease, and the condition is unstable or uncontrollable; * Subjects with clinically significant gastrointestinal bleeding or thrombosis or embolic events within 6 months; * Untreated hepatitis infection: HBV DNA\>2000IU/ml or10000 copies/ml, HCV RNA\> 1000copy/ml, both HbsAg and anti-HCV body are positive; * Evidence of active pulmonary tuberculosis (TB); * Positive test of immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS); * Pleural effusion, ascites and pericardial effusion with clinical symptoms or needing drainage;